Postoperative Stimulated Thyroglobulin of Less Than 1 ng/mL as a Criterion to Spare Low-Risk Patients with Papillary Thyroid Cancer from Radioactive Iodine Ablation

被引:56
|
作者
Rosario, Pedro Weslley [1 ,2 ]
Campos Mineiro Filho, Augusto Flavio [1 ]
Senna Prates, Brenda Sa [1 ]
Oliveira Silva, Livia Cristina [1 ]
Calsolari, Maria Regina [2 ]
机构
[1] Santa Casa Belo Horizonte, Postgrad Program, BR-30150240 Belo Horizonte, MG, Brazil
[2] Santa Casa Belo Horizonte, Serv Endocrinol, BR-30150240 Belo Horizonte, MG, Brazil
关键词
REMNANT ABLATION; SERUM THYROGLOBULIN; CARCINOMA; RECURRENCE; MANAGEMENT; SMALLER; CM;
D O I
10.1089/thy.2012.0190
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Stimulated thyroglobulin (Tg) <= 1 ng/mL after thyroidectomy (after L-thyroxine [L-T4] withdrawal or administration of recombinant human thyrotropin [rhTSH]) has been proposed as a criterion to spare patients with papillary thyroid cancer (PTC), who are at low risk of recurrence, from ablation with iodine-131 (131 I). The objective of this prospective study was to evaluate the recurrence rate using this approach. Methods: This prospective study included 136 patients with PTC who underwent total thyroidectomy with apparently complete tumor resection and who presented no signs of persistent disease after surgery. The patients were classified as low risk of recurrence (nonaggressive histology, T1b-3 N0 M0). All patients had stimulated Tg <= 1 ng/mL, negative anti-Tg antibodies (TgAb), and neck ultrasound (US) showing no anomalies similar to 16 weeks after thyroidectomy, and none of them were submitted to ablation with 131 I. The time of follow-up ranged from 12 to 72 months (median: 44 months). Results: Among the patients studied, 134 (98.5%) continued to have serum Tg concentrations of <1 ng/mL during therapy with L-T4 (Tg/T4) and had negative TgAb and neck US. Lymph node metastases were detected by neck US in one patient. An increase of TgAb was observed in another patient, but she has not developed apparent disease to date. There was only one case of recurrence even among the 60 patients with tumors >4 cm or minimal extrathyroid invasion (T3 N0 M0). Conclusions: Low-risk patients with PTC who have stimulated Tg <= 1 ng/mL after thyroidectomy do not require ablation with I-131.
引用
收藏
页码:1140 / 1143
页数:4
相关论文
共 50 条
  • [31] Impact on Overall Survival of Radioactive Iodine in Low-Risk Differentiated Thyroid Cancer Patients
    Schvartz, Claire
    Bonnetain, Franck
    Dabakuyo, Sandrine
    Gauthier, Melanie
    Cueff, Adele
    Fieffe, Sandrine
    Pochart, Jean-Marie
    Cochet, Inna
    Crevisy, Elodie
    Dalac, Audrey
    Papathanassiou, Dimitri
    Toubeau, Michel
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (05): : 1526 - 1535
  • [32] Post-operative radioactive iodine administration in patients with low-risk thyroid cancer
    Sophie Leboulleux
    Isabelle Borget
    Martin Schlumberger
    Nature Reviews Endocrinology, 2022, 18 : 585 - 586
  • [33] Post-operative radioactive iodine administration in patients with low-risk thyroid cancer
    Leboulleux, Sophie
    Borget, Isabelle
    Schlumberger, Martin
    NATURE REVIEWS ENDOCRINOLOGY, 2022, 18 (10) : 585 - 586
  • [34] Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer
    Sezer, Havva
    Yazici, Dilek
    Terzioglu, Tarik
    Tezelman, Serdar
    Canbaz, Hande Bulut
    Yerlikaya, Aslihan
    Demirkol, Mehmet Onur
    Kapran, Yersu
    Colakoglu, Bulent
    Cilingiroglu, Eda Nur
    Alagol, Faruk
    AMERICAN SURGEON, 2023, 89 (12) : 5996 - 6004
  • [35] APPLICATION OF POST-SURGICAL STIMULATED THYROGLOBULIN FOR RADIOIODINE REMNANT ABLATION SELECTION IN LOW-RISK PAPILLARY THYROID CARCINOMA COMMENTARY
    Terris, David J.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2010, 32 (06): : 698 - 699
  • [36] Is postablation whole-body 131I scintigraphy still necessary in intermediate-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin &lt;1 ng/mL?
    Liu, Bin
    Chen, Yu
    Jiang, Lisha
    He, Ying
    Huang, Rui
    Kuang, Anren
    CLINICAL ENDOCRINOLOGY, 2017, 86 (01) : 134 - 140
  • [37] Comparison between low and high radioactive iodine (131I) ablation dose in patients with low risk of papillary thyroid cancer
    el Bez, I. G. E.
    Slim, I.
    Ben Ghachem, T.
    Yeddes, I.
    Meddeb, I.
    Zaabar, L.
    Ben Sellem, D.
    Ltaief, B.
    Mhiri, A.
    Ben Slimene, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S732 - S733
  • [38] Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer
    Caglar, Meltem
    Bozkurt, Fani M.
    Akca, Ceren Kapulu
    Vargol, Sezen Elhan
    Bayraktar, Miyase
    Ugur, Omer
    Karaagaoglu, Ergun
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (03) : 268 - 274
  • [39] Radioactive iodine use in patients with low- and intermediate-risk papillary thyroid cancer
    Nixon, Iain J.
    Ganly, Ian
    FUTURE ONCOLOGY, 2013, 9 (07) : 921 - 923
  • [40] Should 'low-risk' thyroid cancer patients with residual thyroglobulin be re-treated with iodine 131?
    Hindie, Elif
    Zanotti-Fregonara, Paolo
    Duron, Francoise
    Keller, Isabelle
    Bouchard, Philippe
    Devaux, Jean-Yves
    CLINICAL ENDOCRINOLOGY, 2007, 66 (03) : 329 - 334